Reduced thrombin generation increases host susceptibility to group A streptococcal infection

Blood

Volumn 113, Issue 6, 2009, Pages 1358-1364

  Sun, Hongmin ^a   Wang, Xixi ^b   Degen, Jay L ^c   Ginsburg, David ^b,d  

^a University of Missouri   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5; FIBRIN; FIBRINOGEN; BLOOD CLOTTING FACTOR 5 LEIDEN; STREPTOKINASE; THROMBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD CLOTTING FACTOR 5 DEFICIENCY; CONTROLLED STUDY; FIBRIN DEPOSITION; FIBRINOGEN DEFECT; HEMOSTASIS; HETEROZYGOTE; HOST RESISTANCE; HOST SUSCEPTIBILITY; MORTALITY; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; SEPSIS; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; SURVIVAL; THROMBIN TIME; THROMBOSIS; ANIMAL; C57BL MOUSE; DISEASE PREDISPOSITION; FEMALE; GROWTH, DEVELOPMENT AND AGING; MALE; METABOLISM; MICROBIOLOGY; MOUSE MUTANT; PATHOGENICITY; PHYSIOLOGY; PROTHROMBIN TIME; STREPTOCOCCUS PYOGENES; SURVIVAL RATE; TRANSGENIC MOUSE;

ANIMALS; DISEASE SUSCEPTIBILITY; FACTOR V; FEMALE; FIBRINOGEN; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PROTHROMBIN TIME; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; STREPTOKINASE; SURVIVAL RATE; THROMBIN;

EID: 60849087371     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-07-170506     Document Type: Article

References (43)

1. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005;5:685-694.
2. Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med. 1996;334:240-245.
3. Bisno AL, Rubin FA, Cleary PP, Dale JB. Prospects for a group A streptococcal vaccine: rationale, feasibility, and obstacles - report of a National Institute of Allergy and Infectious Diseases workshop. Clin Infect Dis. 2005;41:1150-1156.
4. Harrington DJ, Sutcliffe IC, Chanter N. The molecular basis of Streptococcus equi infection and disease. Microbes Infect. 2002;4:501-510.
5. Marcum JA, Kline DL. Species specificity of streptokinase. Comp Biochem Physiol B. 1983;75:389-394.
6. Nowicki ST, Minning-Wenz D, Johnston KH, Lottenberg R. Characterization of a novel streptokinase produced by Streptococcus equisimilis of non-human origin. Thromb Haemost. 1994;72:595-603.
7. McCoy HE, Broder CC, Lottenberg R. Streptoki-nases produced by pathogenic group C streptococci demonstrate species-specific plasminogen activation. J Infect Dis. 1991;164:515-521.
8. Schroeder B, Boyle MD, Sheerin BR, Asbury AC, Lottenberg R. Species specificity of plasminogen activation and acquisition of surface-associated proteolytic activity by group C streptococci grown in plasma. Infect Immun. 1999;67:6487-6495.
9. Boxrud PD, Fay WP, Bock PE. Streptokinase binds to human plasmin with high affinity, perturbs the plasmin active site, and induces expression of a substrate recognition exosite for plasminogen. J Biol Chem. 2000;275:14579- 14589.
10. Sun H, Ringdahl U, Homeister JW, et al. Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. Science. 2004;305:1283-1286.
11. Esmon CT, Mather T. Switching serine protease specificity. Nat Struct Biol. 1998;5:933-937.
12. Sodeinde OA, Subrahmanyam YV, Stark K, et al. A surface protease and the invasive character of plague. Science. 1992;258:1004-1007.
13. Boyle MD, Lottenberg R. Plasminogen activation by invasive human pathogens. Thromb Haemost. 1997; 77:1-10.
14. Engleberg NC, Heath A, Miller A, Rivera C, DiRita VJ. Spontaneous mutations in the CsrRS two-component regulatory system of Streptococcus pyo-genes result in enhanced virulence in a murine model of skin and soft tissue infection. J Infect Dis. 2001;183:1043-1054.
15. Suh TT, Holmback K, Jensen NJ, et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev. 1995; 9:2020-2033.
16. Flick MJ, Du X, Witte DP, et al. Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaM-beta2/Mac-1 is critical for host inflammatory response in vivo. J Clin Invest. 2004;113:1596-1606.
17. Sun H, Yang TL, Yang A, Wang X, Ginsburg D. The murine platelet and plasma factor V pools are biosynthetically distinct and sufficient for minimal hemostasis. Blood. 2003;102:2856-2861.
18. Cui J, Eitzman DT, Westrick RJ, et al. Spontaneous thrombosis in mice carrying the factor V Leiden mutation. Blood. 2000;96:4222-4226.
19. Asselta R, Tenchini ML, Duga S. Inherited defects of coagulation factor V: the hemorrhagic side. J Thromb Haemost. 2006;4:26-34.
20. Coughlin SR. Thrombin signalling and protease-acti-vated receptors. Nature. 2000;407:258-264.
21. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem. 1989;264:4743-4746.
22. Flick MJ, Du X, Degen JL. Fibrin(ogen)-alpha M beta 2 interactions regulate leukocyte function and innate immunity in vivo. Exp Biol Med (Maywood). 2004; 229:1105-1110.
23. De S, V, Leone G. Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia. Haematologica. 1995;80:344-356.
24. Franco RF, Reitsma PH. Genetic risk factors of venous thrombosis. Hum Genet. 2001;109:369-384.
25. Price DT, Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med. 1997;127:895-903.
26. Kerlin BA, Yan SB, Isermann BH, et al. Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood. 2003;102:3085-3092.
27. Cui J, O'Shea KS, Purkayastha A, Saunders TL, Ginsburg D. Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V. Nature. 1996;384:66-68.
28. Sun WY, Witte DP, Degen JL, et al. Prothrombin deficiency results in embryonic and neonatal lethality in mice. Proc Natl Acad Sci U S A. 1998;95:7597-7602.
29. Xue J, Wu Q, Westfield LA, et al. Incomplete embryonic lethality and fatal neonatal hemorrhage caused by prothrombin deficiency in mice. Proc Natl Acad Sci U S A. 1998;95:7603-7607.
30. Castoldi E, Brugge JM, Nicolaes GA, et al. Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations. Blood. 2004;103:4173-4179.
31. Allen GA, Wolberg AS, Oliver JA, et al. Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. J Thromb Haemost. 2004;2:402-413.
32. Levi M, ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999;341:586-592.
33. Gould WR, Silveira JR, Tracy PB. Unique in vivo modifications of coagulation factor V produce a physically and functionally distinct platelet-derived cofactor: characterization of purified platelet-derived factor V/Va. J Biol Chem. 2004;279:2383-2393.
34. von HP, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res. 2007;100:27-40.
35. Elzey BD, Sprague DL, Ratliff TL. The emerging role of platelets in adaptive immunity. Cell Immunol. 2005;238:1-9.
36. Boyle MD, Lottenberg R. The interaction of pathogens with humans. Methods. 2000;21:99-102.
37. Esmon CT. The protein C pathway. Chest. 2003; 124[Suppl]:26-32.
38. Dean M, Carrington M, O'Brien SJ. Balanced polymorphism selected by genetic versus infectious human disease. Annu Rev Genomics Hum Genet. 2002;3:263-292.
39. Coleman JL, Benach JL. Use of the plasminogen activation system by microorganisms. J Lab Clin Med. 1999;134:567-576.
40. Herwald H, Cramer H, Morgelin M, et al. M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. Cell. 2004;116:367-379.
41. Lahteenmaki K, Kuusela P, Korhonen TK. Bacterial plasminogen activators and receptors. FEMS Micro-biol Rev. 2001;25:531-552.
42. Sun H. The interaction between pathogens and the host coagulation system. Physiology. 2006;21:281-288.
43. Peters LL, Cheever EM, Ellis HR, et al. Large-scale, high-throughput screening for coagulation and he-matologic phenotypes in mice. Physiol Genom. 2002;11:185-193.